2026-05-22T05:28:02Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/184462024-02-19T15:30:47Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Falco, Agustín author de Oliveira, Thiago Bueno author Cacicedo, Jon author Ospina, Aylen Vanessa author Ticona, Miguel Ángel author Galindo, Héctor author Pereira, Marcos David author Aguilar-Ponce, José Luis author Rueda-Domínguez, Antonio author Soria, Tannia author Taberna, Miren author Iglesias, Lara author Sowley, Taysser author Mesía, Ricard author TTCC group (Spanish Group for the Treatment of the Head and Neck Cancer) author 2021-08-26 Cisplatin is the standard of treatment for squamous cell carcinoma of the head and neck (SCCHN) that has demonstrated efficacy, either in locally advanced disease when combined with radiotherapy at high doses, or in metastatic/recurrent disease when combined with other agents. However, the usual toxicities related to cisplatin, such as neurotoxicity, nephrotoxicity, ototoxicity, and hematologic toxicities, especially when high doses have been administered, have important implications in the patients' quality of life. The decision to administer cisplatin depends on several patient factors, such as age, performance status, weight loss, comorbidities, previous toxicities, chronic viral infection, or even the current SARS-CoV-2 pandemic. In order to establish recommendations for the management of patients with SCCHN, a group of experts in medical and radiation oncology from Spain and Latin-American discussed how to identify patients who are not candidates for cisplatin to offer them the most suitable therapeutic alternative. 10.2147/CMAR.S322411 1179-1322 Cancer management and research http://hdl.handle.net/10668/18490 34471383 http://hdl.handle.net/20.500.12105/18446 age cisplatin comorbidities contraindication frailty toxicity Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice.